2 results
Approved WMOCompleted
To investigate safety and tolerability as well as the induced immune response upon MesoPher/mitazalimab combination therapy in metastasized pancreatic disease after (modified) FOLFIRINOX.
Approved WMORecruiting
PART I:Primary:• To investigate the safety and tolerability of two doses of VAD044 administered daily for up to 12 weeks in HHT patients.Secondary:• To assess the effects of two doses of VAD044 for up to 12 weeks of treatment on:o Epistaxis:•…